What to Know About a DMSO Oral Dose, Uses, and Risks

Dimethyl sulfoxide, better known as DMSO, is a colorless liquid originally derived as a by-product of wood pulp processing in the paper industry, and it has been studied for medical use since the 1960s.¹ Despite decades of research, the FDA has approved DMSO for only one clinical indication in humans, and that approval is for bladder instillation rather than oral use. Oral DMSO has nonetheless been explored in a handful of clinical settings, and it circulates widely in alternative health communities as a supplement. Understanding what the evidence actually shows, and where the gaps are, matters if you are considering it.

What DMSO Does in the Body

DMSO’s unusual reputation comes from a few distinctive biological properties. It penetrates skin and other biological membranes remarkably well, and it can carry other dissolved substances along with it. Lab research shows that DMSO alters the mechanical properties of cell membranes in a concentration-dependent way, increasing permeability even at relatively low concentrations of about 3% and above.² This membrane-penetrating ability is what makes it useful as a solvent in laboratories and what sparked interest in it as a drug delivery vehicle.

Beyond acting as a carrier, DMSO has its own pharmacological activity. It scavenges hydroxyl radicals, which are reactive molecules that damage tissue during inflammation and injury. In laboratory studies, it reduced both lipid peroxidation and protein damage caused by oxidative stress in brain tissue.³ Separate research found that it impairs platelet aggregation at injury sites and eliminates the accompanying widening of blood vessels, effects attributed to its hydroxyl radical scavenging.⁴

DMSO also appears to block pain signals directly. When applied to exposed nerve tissue in cats, it slowed conduction in C-type nerve fibers, the small, slow fibers that carry pain sensation. At concentrations of about 9% and above, it completely blocked C fiber conduction, and the onset of this block was almost immediate at 15% or higher.⁵ This C fiber blockade may account for the pain relief people sometimes report when applying DMSO topically.

How an Oral Dose Is Absorbed and Eliminated

When DMSO is taken by mouth, it gets into the bloodstream fast. Animal pharmacokinetic studies provide the most detailed picture we have. In horses given oral DMSO, the compound’s absorption half-life was extremely short, about nine minutes on average, meaning it enters the blood almost as soon as it reaches the gut. Plasma concentrations peaked between 15 minutes and 4 hours post-dose. Roughly half the oral dose was absorbed into systemic circulation over a 24-hour period, and the elimination half-life was around 15 to 16 hours.⁶

Primate data tells a broadly consistent story. Rhesus monkeys given daily oral doses had DMSO appear rapidly in blood, reaching steady-state levels after about one day. Once dosing stopped, DMSO itself cleared from the blood within roughly 72 hours, with a half-life of about 16 hours. But its primary metabolite, dimethyl sulfone, lingered longer, taking around five days to fully clear and carrying a half-life of about 38 hours. Most of the dose, around 60%, was excreted unchanged in urine, and another 16% left as the sulfone metabolite. None was detected in feces.⁷ The researchers concluded that DMSO absorption in monkeys is similar to what happens in humans, though monkeys metabolize and excrete it faster.

One practical consequence of all this metabolism: some DMSO is converted to dimethyl sulfide, a volatile sulfur compound that your body exhales through the lungs and releases through the skin. This produces a distinctive garlic-like or oyster-like breath and body odor that can persist for hours or even days. The monkey study confirmed this indirectly, noting the “particular sweetness” of the animals’ breath during treatment.⁷ In human clinical use, patients consistently flag this odor as one of their primary complaints about DMSO therapy.

The One FDA-Approved Use

Despite the broad range of properties researchers have documented, the FDA has approved DMSO for exactly one condition: interstitial cystitis, also called bladder pain syndrome. The approved product is Rimso-50, a 50% DMSO solution that is instilled directly into the bladder through a catheter. This approval came in 1978, and the American Urological Association still lists it as a treatment option, though the evidence supporting it is graded at level C, meaning it rests on expert opinion and lower-quality studies rather than large randomized trials.⁸

A small study of 10 patients with biopsy-confirmed interstitial cystitis found that nine responded favorably to self-administered DMSO instillations via intermittent self-catheterization. The technique was reported as well tolerated and without complications.⁹ Even in this approved context, though, the treatment is delivered directly to the bladder wall rather than taken by mouth. There is no FDA-approved oral DMSO product for any condition.

Oral DMSO in Amyloidosis Research

The clinical setting where oral DMSO has received the most sustained research attention is systemic amyloidosis, a group of diseases in which misfolded proteins build up in organs and progressively damage them. Several small studies from the 1980s and later explored whether oral DMSO could slow or reverse this damage, particularly the kidney involvement that often proves fatal.

A Dutch study treated 13 patients with systemic amyloidosis using prolonged oral DMSO. In the seven patients with secondary amyloidosis (the type triggered by chronic inflammatory conditions), the researchers observed clear improvement in kidney function after three to six months. Creatinine clearance rose by 30 to 100%, and protein loss in the urine declined. The improvement held as long as patients continued taking DMSO. The researchers concluded that a trial of oral DMSO was warranted for all patients with secondary amyloidosis, noting the treatment was “unpleasant but bears no exceptional risks,” though they expressed doubt about whether it actually dissolved existing amyloid deposits.¹⁰

A later Japanese retrospective review of 15 patients with amyloidosis complicating chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease found that oral DMSO treatment was considered successful in about two-thirds of them. Eight weeks of treatment improved kidney function and protein loss in half the patients with kidney involvement, and gastrointestinal symptoms like diarrhea improved in six patients. No serious side effects were reported.¹¹ However, the treatment did not help patients who already had severe or advanced kidney dysfunction, suggesting there may be a window of opportunity beyond which the damage cannot be reversed.

An Italian study of four patients found similar patterns: oral DMSO produced no benefit in two patients with primary amyloidosis (a different subtype) but did improve kidney function and reduce inflammatory activity in two patients with secondary amyloidosis linked to rheumatoid arthritis.¹² The distinction between amyloidosis subtypes appears to matter: oral DMSO may offer something for the secondary (AA) form driven by chronic inflammation, while the primary (AL) form seems unresponsive.

All of these studies share the same limitation: they are small, uncontrolled, and retrospective or open-label. No large randomized trial of oral DMSO for amyloidosis has ever been conducted. The research essentially stopped progressing after the 1980s and 1990s, likely because newer biologic drugs for the underlying inflammatory diseases reduced the incidence of secondary amyloidosis in the first place. If you encounter claims that DMSO “cures amyloidosis,” the actual evidence is far more modest and limited to one subtype.

Osteoarthritis and Pain Relief

DMSO has also been studied for osteoarthritis, though mostly as a topical treatment rather than an oral one. A systematic review identified four double-blind randomized controlled trials of topical DMSO for knee osteoarthritis, with mixed results. One trial found DMSO performed no better than placebo, while another found significant pain reduction even at a dose below the suggested optimal concentration. A third large trial powered for a different primary comparison found DMSO had the same analgesic effect as placebo. And a comparator trial suggested DMSO gel was roughly equivalent to a standard topical anti-inflammatory drug.¹³

A meta-analysis that pooled DMSO and its dietary derivative methylsulfonylmethane (MSM) together found a statistically significant pain reduction of about 6 mm on a 100-mm pain scale compared to placebo. That sounds like it works, but the researchers pointed out that this change falls below the threshold of clinical significance: a patient would need to see roughly a 10-to-18 mm improvement to actually notice a meaningful difference. On top of that, the results across trials were inconsistent, and when analyzed with a stricter statistical model, the overall finding was no longer quite significant.¹⁴ The honest summary is that DMSO might produce a small real effect on osteoarthritis pain, but the effect is too small and inconsistent to be clinically meaningful based on current evidence.

Side Effects and Safety Concerns

A systematic review of adverse reactions to DMSO in humans across all routes of administration found that gastrointestinal and skin reactions were the most commonly reported problems. Nausea and vomiting topped the list of gut-related complaints. Most reactions were transient and mild, often lasting only minutes to a few hours, and did not require medical intervention.¹⁵ The review also identified a dose-response relationship: higher DMSO doses produced more frequent adverse reactions.¹⁶

One case in the review described a severe episode of nausea, vomiting, and abdominal cramps in a patient who had an acute allergic reaction, but this was an outlier. The clinical studies of oral DMSO for amyloidosis consistently reported that the main complaints were mild nausea and the persistent unpleasant breath and body odor. No serious organ toxicity was reported in those treatment courses, which lasted months.

That relatively benign short-term safety profile can create a false sense of security. DMSO is an industrial solvent that is readily available in hardware stores and online, and the purity of non-pharmaceutical-grade products varies widely. Industrial-grade DMSO may contain contaminants, and because DMSO so efficiently carries dissolved substances through membranes, those contaminants can be pulled into your bloodstream along with it. If you are going to use DMSO at all, pharmaceutical-grade material is the minimum standard, and even then, you are working without the safety net of FDA oversight for oral dosing.

Drug Interactions and the Carrier Effect

The same membrane-penetrating property that makes DMSO interesting as a solvent also makes it a concern when combined with other medications. Research has shown that when drugs are mixed with DMSO, many appear to be potentiated in their effect, meaning that smaller doses produce the same therapeutic response. While that sounds useful in theory, it also means that a drug dose calibrated for normal absorption could become effectively an overdose if DMSO increases how much of it reaches the bloodstream.¹⁷

This is not a hypothetical concern. In veterinary medicine, where DMSO is used more widely, standard references explicitly warn that it can potentiate the effects of co-administered drugs.¹⁸ If you take oral DMSO alongside prescription medications, there is no standard pharmacokinetic data telling you how much the absorption of those medications might change. Blood thinners, sedatives, and diabetes drugs, any medication where a dose increase could be dangerous, deserve particular caution. Anyone considering oral DMSO should tell their prescribing doctor, and the reality is that most physicians will not have detailed clinical guidance to offer because the interaction data barely exists in humans.

Veterinary Use Versus Human Self-Dosing

DMSO has a much more established place in veterinary medicine, particularly for horses. Equine practitioners use it for trauma to the central nervous system, inflammation of tendons and joints, laminitis, chronic endometritis, and ischemic bowel conditions during abdominal surgery. Its ability to reduce connective tissue formation is considered potentially useful in preventing adhesions after surgery. The common veterinary dose for horses is 1 gram per kilogram of body weight given intravenously as up to a 40% solution, with a maximum treatment duration of five days.¹⁸

The existence of legitimate veterinary use has led some people to reason that DMSO must be safe for human oral consumption at similar weight-adjusted doses. This logic has gaps. Veterinary doses are given under professional supervision with pharmaceutical-grade material, treatment duration is limited, and horses metabolize drugs differently than people do. The rhesus monkey data suggests that DMSO metabolism is slower in humans than in other species, which could mean that a dose calculated by simple body-weight scaling stays in your system longer than expected.⁷

Brain Edema and Intravenous Research

Some of the most striking experimental findings with DMSO involve its effects on brain swelling, though these studies used intravenous rather than oral dosing. In rabbits with experimentally induced brain edema, a three-hour intravenous DMSO infusion produced a progressive and sustained reduction in intracranial pressure, with the lowest point reached at the end of the infusion. Brain water content dropped, and sodium content in the brain decreased as well, all without significant changes in blood pressure or central venous pressure.¹⁹ These results have fueled interest in DMSO as a neuroprotective agent, but the research remains in animal models and has not translated into approved human treatment for brain injuries or stroke.

Eye disease research has shown a similar pattern: DMSO appears to produce favorable outcomes in human eye diseases with low or no observed ocular or systemic toxicity, but again, the evidence base remains thin and the applications are not yet standardized or widely adopted. The recurring theme across DMSO research is promising early-stage findings that never quite advanced to the large clinical trials needed for regulatory approval. Whether this reflects a genuine lack of efficacy at human therapeutic doses, a lack of commercial incentive to fund those trials for a cheap, unpatentable compound, or some combination of the two is a matter of ongoing debate among researchers who have worked with the substance.

Why Purity and Source Matter More Than Usual

Because DMSO is available cheaply as an industrial solvent, people who self-administer it orally often purchase non-pharmaceutical-grade material. This creates a unique risk that does not apply to most supplements or medications. DMSO’s defining characteristic is that it increases the permeability of biological membranes and carries other dissolved molecules through them.¹⁷ An impure DMSO product does not just expose you to its own contaminants in the normal way; it actively shuttles those contaminants into your tissues more efficiently than they would get there on their own. Trace heavy metals, residual solvents, or bacterial endotoxins that would pass through your gut with minimal absorption might instead be driven across mucosal barriers.

If you are going to use DMSO orally, look for products specifically labeled as pharmaceutical grade or USP grade, and purchase from suppliers who provide certificates of analysis. Even then, you are stepping outside the bounds of any approved dosing protocol. The clinical studies of oral DMSO for amyloidosis used controlled preparations under medical oversight, and the researchers still acknowledged that the treatment was “unpleasant.” They tolerated the side effects because the alternative for their patients was progressive organ failure. For someone exploring DMSO for joint pain or general wellness, that risk-benefit calculation looks very different.

How DMSO Differs From MSM

Methylsulfonylmethane, commonly sold as MSM, is the primary metabolite that DMSO breaks down into inside your body. MSM is widely marketed as a joint health supplement, and some people assume it is simply a safer, odor-free form of DMSO. The two compounds are chemically related but pharmacologically distinct. DMSO’s membrane-penetrating and drug-carrying properties do not carry over to MSM. The meta-analysis that pooled DMSO and MSM trials together for osteoarthritis found that neither produced clinically meaningful pain relief on its own.¹⁴ If you are taking MSM for joint support, that is a different conversation with a different evidence base than taking DMSO by mouth. And if you are taking DMSO specifically because you think it provides the benefits of MSM plus extra properties, you are also accepting DMSO’s extra risks, including the breath odor, the gastrointestinal side effects, and the potential to alter how your other medications are absorbed.

The primate pharmacokinetic data is relevant here too. After oral DMSO, the sulfone metabolite (MSM) took about four days to reach steady state and lingered in the blood for about five days after DMSO dosing stopped, with a half-life of 38 hours.⁷ So if MSM is what you actually want, taking DMSO is an inefficient and riskier way to get it. Your body converts under half the DMSO dose to MSM, and the rest stays as DMSO or gets exhaled as the sulfide compound responsible for the odor. You could simply take MSM directly and skip the intermediate compound entirely.